SC 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Paratek Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

699374302

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

CUSIP No. 699374302 13G Page 2 of 9

1	NAME OF REPORTING PERSONS   Highland Capital Management, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ☐        (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES   BENEFICIALLY   OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER   0**
	6	SHARED VOTING POWER   2,204,865**
	7	SOLE DISPOSITIVE POWER   0**
	8	SHARED DISPOSITIVE POWER   2,204,865**

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   2,204,865**
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   6.9%**
12	TYPE OF REPORTING PERSON*   IA, PN

* SEE INSTRUCTIONS BEFORE FILLING OUT

** SEE ITEM 4.

CUSIP No. 699374302 13G Page 3 of 9

1	NAME OF REPORTING PERSONS   Strand Advisors, Inc.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ☐        (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES   BENEFICIALLY   OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER   0
	6	SHARED VOTING POWER   2,204,865**
	7	SOLE DISPOSITIVE POWER   0
	8	SHARED DISPOSITIVE POWER   2,204,865**

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   2,204,865**
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   6.9%**
12	TYPE OF REPORTING PERSON*   HC, CO

* SEE INSTRUCTIONS BEFORE FILLING OUT

** SEE ITEM 4.

CUSIP No. 699374302 13G Page 4 of 9

1	NAME OF REPORTING PERSONS   James D. Dondero
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a)  ☐        (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   United States

NUMBER OF SHARES   BENEFICIALLY   OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER   0
	6	SHARED VOTING POWER   3,153,028**
	7	SOLE DISPOSITIVE POWER   0
	8	SHARED DISPOSITIVE POWER   3,153,028**

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,153,028**
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   9.8%**
12	TYPE OF REPORTING PERSON*   HC, IN

* SEE INSTRUCTIONS BEFORE FILLING OUT

** SEE ITEM 4.

SCHEDULE 13G

This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Highland Capital Management, L.P., a Delaware limited partnership (“Highland Capital”), Strand Advisors, Inc., a Delaware corporation (“Strand”), and James D. Dondero (collectively, the “Reporting Persons”).

James D. Dondero is the President of Strand. Highland Capital serves as the investment advisor to a certain private fund (the “HCM Fund”). This Schedule 13G relates to the Common Stock, par value $0.001 per share (the “Common Stock”), of Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), held by (i) the HCM Fund, (ii) certain other funds and managed accounts ultimately advised by James D. Dondero (together with the HCM Fund, the “Funds”) and (iii) a trust, the shares held by which James D. Dondero has the right to acquire beneficial ownership of (the “Trust”).

Item 1(a) Name of Issuer.

Paratek Pharmaceuticals, Inc.

Item 1(b) Address of Issuer’s Principal Executive Offices.

75 Park Plaza

Boston, Massachusetts 02116

Item 2(a) Name of Person Filing.

(1) Highland Capital Management, L.P.

(2) Strand Advisors, Inc.

(3) James D. Dondero

Item 2(b) Address of Principal Business Office, or, if none, Residence.

For all Filers:

300 Crescent Court, Suite 700

Dallas, Texas 75201

Item 2(c) Citizenship or Place of Organization.

(1) Highland Capital Management, L.P. is a Delaware limited partnership

(2) Strand Advisors, Inc. is a Delaware corporation

(3) James D. Dondero is a United States citizen

Item 2(d) Title of Class of Securities.

Common Stock, par value $0.001 per share

Item 2(e) CUSIP Number.

699374302

5

Item 3 Reporting Person.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

(a)	☐	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	☐	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	☒	An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).
(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
(g)	☒	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j)	☐	Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4 Ownership.

(a) As the investment manager of the HCM Fund, Highland Capital and Strand, as the general partner of Highland Capital, may be deemed the beneficial owners of the 2,204,865 shares of Common Stock held by the HCM Fund.

Mr. Dondero may be deemed the beneficial owner of the 3,153,028 shares of Common Stock held by the Funds and the Trust.

(b) Highland Capital and Strand may be deemed the beneficial owner of 6.9% of the outstanding Common Stock. This percentage was determined by dividing 2,204,865, the number of shares of Common Stock held directly by the HCM Fund, by 32,140,977, which is the number of shares of Common Stock outstanding as of October 31, 2018 according to the Issuer’s Quarterly Report on Form 10-Q filed with the Securities Exchange Commission on November 6, 2018.

6

Mr. Dondero may be deemed the beneficial owner of 9.8% of the outstanding Common Stock. This percentage was determined by dividing 3,153,028, the number of shares of Common Stock held directly by the Funds and the Trust, by 32,140,977, which is the number of shares of Common Stock outstanding as of October 31, 2018 according to the Issuer’s Quarterly Report on Form 10-Q filed with the Securities Exchange Commission on November 6, 2018.

(c) Highland Capital and Strand have the shared power to vote and dispose of the 2,204,865 shares of Common Stock held by the HCM Fund.

Mr. Dondero has the the shared power to vote and dispose of the 3,153,028 shares of Common Stock held by the Funds and the Trust.

Item 5 Ownership of Five Percent or Less of a Class.

Inapplicable.

Item 6 Ownership of More Than Five Percent on Behalf of Another Person.

Inapplicable.

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

Inapplicable.

Item 8 Identification and Classification of Members of the Group.

Inapplicable.

Item 9 Notice of Dissolution of Group.

Inapplicable.

Item 10 Certification.

By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

7

Exhibits	Exhibit 99-1
	Joint Filing Agreement, dated February 14, 2019, by and among Highland Capital, Strand and James D. Dondero.

8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2019

HIGHLAND CAPITAL MANAGEMENT, L.P.
By:	Strand Advisors, Inc., its general partner
	By:	/s/ James D. Dondero
		Name: James D. Dondero
		Title: President
STRAND ADVISORS, INC.
By:	/s/ James D. Dondero
Name: James D. Dondero
Title: President
/s/ James D. Dondero
James D. Dondero

.

EX-99.1

EXHIBIT 99-1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Paratek Pharmaceuticals, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 14, 2019.

HIGHLAND CAPITAL MANAGEMENT, L.P.
By:	Strand Advisors, Inc., its general partner
	By:	/s/ James D. Dondero
		Name: James D. Dondero
		Title: President
STRAND ADVISORS, INC.
By:	/s/ James D. Dondero
Name: James D. Dondero
Title: President
/s/ James D. Dondero
James D. Dondero